China Pediatric Slowdown Prompts Abbott Caution
Slowing growth in China, particularly in some consumer sectors, has prompted words of caution from Abbott over the outlook for the remainder of the year, although its CEO remains positive on this key emerging market.
You may also be interested in...
Moving from a mixed to a more pessimistic outlook, top executives at multinational drug firms see China as fast losing its shine, despite the country continuing to lead growth in the emerging markets. PharmAsia News has combed through quarterly earnings reports to bring you the winners, laggards and most successful growth strategies in this increasingly challenging market.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.